This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ABX-MA1

Amgen, Inc.

Drug Names(s): ABX-MA1

Description: ABX-MA1 is a XenoMouse-derived fully human monoclonal antibody that binds to MUC18. MUC18 is also expressed on the cell surfaces of sarcomas, including smooth muscle and blood vessel-derived sarcomas, prostate and renal cell cancers making these potential future indications.Relevant peer-reviewed, published preclinical literature demonstrates that MUC18 and related molecules are appropriate therapeutic targets for malignant melanoma.

Partners: AstraZeneca PLC


ABX-MA1 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug